简体中文
EnglishWhat Recent Progress and Future Goals Does Roche Report?
Updated
Roche's most recent public update centers on three points: group sales rose 6% (CER) in the first nine months of 2026, the company says it made meaningful progress this quarter in areas where patients urgently need better treatment options, and it now aims to bring up to 20 new medicines to patients by 2030. These figures and goals come from Roche's own website and are best read as company-reported progress, not independent verification.
The reported results at a glance
| Item | What Roche reports | Source on roche.com |
|---|---|---|
| Nine-month 2026 sales | +6% at constant exchange rates (CER) | "In the spotlight" / nine months results 2026 |
| Half-year 2026 sales | CHF 30.4 billion | Investor information section |
| FY 2025 dividend yield | 3.2% | Investor information section |
| Next scheduled report | 28 January 2027 | Investor information section |
| New medicines goal | Up to 20 new medicines by 2030 | CEO statement, Dr Thomas Schinecker |
Two caveats when using these numbers. First, the 6% growth is stated in CER terms, which strips out currency swings; it is not the same as reported growth in Swiss francs. Second, the CHF 30.4 billion figure covers the first half of 2026, so it is a different period from the nine-month growth rate and the two should not be combined into a single calculation.
What the CEO says about progress
The site quotes CEO Dr Thomas Schinecker saying that "this quarter, we made meaningful progress in areas where patients urgently need better treatment options," followed by the 2030 goal of up to 20 new medicines. Read together, the statement frames the pipeline goal as the forward-looking counterpart to recent quarterly progress rather than as a standalone promise. The site does not, in the material available, list which specific programs drove that quarterly progress.
Where the supporting detail lives
Roche points readers to two places for the fuller picture:
- Annual Report — described as the place where the company details how it improved outcomes for patients, using its combined Diagnostics and Pharmaceuticals strengths.
- Media center — where quarterly updates and announcements are published.
If you want to check the 2030 medicines target against actual pipeline disclosures, the Annual Report and the quarterly reporting are the documents to follow, with the next scheduled update on 28 January 2027.
How this fits Roche's stated strategy
The reported progress is presented against a three-part mission the site lays out explicitly:
- Prevent — identify high-risk patients early so medicines can be used in time.
- Stop — diagnose accurately and deliver targeted medicines to halt disease progression.
- Cure — identify the cause of a condition and restore health through curative medicines.
The diagnostics side supports the "stop" step, while the pharma side supports "cure." This is why the company describes the two businesses as combined strengths rather than separate divisions. The 20-medicines goal sits within the pharma arm of that framework.
Practical takeaways
- Use the 6% CER figure for trend direction, and treat CHF 30.4 billion as a half-year absolute number — don't mix periods.
- Treat the 2030 goal as a stated ambition with a public deadline, and track it through annual and quarterly reports rather than assuming a fixed annual pace.
- For anything time-sensitive, the site's own calendar gives 28 January 2027 as the next reporting date; check the Investor center closer to that date for confirmation.